ArticleContemporary oncology (Poznan, Poland)2026
Anticancer effects of fangchinoline in 4T1 breast cancer cells:
Article in Contemporary oncology (Poznan, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis and limited therapeutic options. Fangchinoline, a bisbenzylisoquinoline alkaloid, has demonstrated anticancer activity; however, its molecular mechanism in TNBC remains unclear. This study aimed to investigate the anticancer effects of fangchinoline and explore its potential molecular mechanisms in TNBC. Material and methods: An integrated Results: Fangchinoline demonstrated strong binding affinity toward TGF-β1 and exhibited selective cytotoxicity against 4T1 cells (IC Conclusions: Fangchinoline exhibits potential anticancer activity against TNBC-cells by inducing apoptosis and affecting key survival-related pathways. Further studies are required to confirm its molecular mechanisms and therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.